DK2054428T3 - Udvikling af bestanddele til denque-virus-vaccine - Google Patents

Udvikling af bestanddele til denque-virus-vaccine

Info

Publication number
DK2054428T3
DK2054428T3 DK07840969.5T DK07840969T DK2054428T3 DK 2054428 T3 DK2054428 T3 DK 2054428T3 DK 07840969 T DK07840969 T DK 07840969T DK 2054428 T3 DK2054428 T3 DK 2054428T3
Authority
DK
Denmark
Prior art keywords
virus vaccine
denque
developing ingredients
ingredients
developing
Prior art date
Application number
DK07840969.5T
Other languages
English (en)
Inventor
Stephen S Whitehead
Joseph E Blaney
Brian R Murphy
Ching-Juh Lai
Original Assignee
Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea filed Critical Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea
Application granted granted Critical
Publication of DK2054428T3 publication Critical patent/DK2054428T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK07840969.5T 2006-08-15 2007-08-15 Udvikling af bestanddele til denque-virus-vaccine DK2054428T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83772306P 2006-08-15 2006-08-15
PCT/US2007/076004 WO2008022196A2 (en) 2006-08-15 2007-08-15 Development of dengue virus vaccine components

Publications (1)

Publication Number Publication Date
DK2054428T3 true DK2054428T3 (da) 2013-08-26

Family

ID=39083099

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07840969.5T DK2054428T3 (da) 2006-08-15 2007-08-15 Udvikling af bestanddele til denque-virus-vaccine
DK12182319.9T DK2589602T3 (da) 2006-08-15 2007-08-15 Udvikling af dengue-virusvaccinekomponenter

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12182319.9T DK2589602T3 (da) 2006-08-15 2007-08-15 Udvikling af dengue-virusvaccinekomponenter

Country Status (15)

Country Link
US (8) US8337860B2 (da)
EP (2) EP2589602B1 (da)
CN (2) CN103602689B (da)
AU (1) AU2007285929B2 (da)
BR (2) BR122020023372B1 (da)
CA (2) CA2661296C (da)
CY (1) CY1118003T1 (da)
DK (2) DK2054428T3 (da)
ES (1) ES2585553T3 (da)
HU (1) HUE029333T2 (da)
LT (1) LT2589602T (da)
PL (1) PL2589602T3 (da)
PT (1) PT2589602T (da)
SI (1) SI2589602T1 (da)
WO (1) WO2008022196A2 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162949A0 (en) * 2002-01-10 2005-11-20 Us Gov Health & Human Serv Construction of west nile virus and dengue virus chimeras for use in a virus vaccine to prevent disease caused by west nile virus
TR201806655T4 (tr) * 2002-05-03 2018-06-21 The Government Of The Secretary Department Of Health And Human Services Dang tipi 4 genomunun 3' translate edilmemiş bölgesinin bir kesitinde bir 30 nükleotit delesyonunu (delta30) içeren bir rden3/4delta 30(me), rden2/4delta30(me) ya da rden1/4delta30(me) rekombinant kimerik dang virüsü olup, burada adı geçen 30 nükleotit delesyonu tl2 stem-loop yapısına karşılık gelir.
HUE029333T2 (en) 2006-08-15 2017-03-28 The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Development of Dengue virus vaccine components
NZ618158A (en) * 2009-06-01 2015-05-29 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
CA2933472A1 (en) 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
CA3177572A1 (en) * 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
AU2014281713A1 (en) 2013-06-21 2015-11-12 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
BR112017008952A2 (pt) * 2014-11-02 2018-01-16 Univ North Carolina Chapel Hill métodos e composições para vírus recombinantes da dengue para desenvolvimento de vacina e diagnóstico
CN106999568A (zh) * 2014-12-22 2017-08-01 默沙东公司 登革病毒疫苗组合物及其使用方法
CA2991212A1 (en) 2015-07-02 2017-01-05 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
EP3353287B1 (en) 2015-09-26 2022-03-09 Primevax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
EP3355916A4 (en) * 2015-09-30 2018-08-29 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
CN109152828A (zh) 2016-03-11 2019-01-04 美国政府(由卫生和人类服务部的部长所代表) 减毒活zika病毒疫苗
WO2018093907A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
WO2018129202A1 (en) * 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
CA3053289A1 (en) * 2017-02-14 2018-08-23 Xuping XIE Live attenuated zika virus with 3'utr deletion, vaccine containing and use thereof
US10240130B2 (en) 2017-02-15 2019-03-26 The Board Of Regents Of The University Of Texas System CDNA clone-launched platform for high-yield production of inactivated zika virus
CN117752780A (zh) 2017-12-07 2024-03-26 默沙东有限责任公司 登革病毒疫苗组合物的制剂
CA3147807A1 (en) 2019-08-16 2021-02-25 Derek WALLACE Methods for preventing dengue and hepatitis a
US20240131197A1 (en) * 2021-02-26 2024-04-25 Duke University Compositions For and Methods of Improving Gene Therapy
WO2023161715A1 (en) * 2022-02-22 2023-08-31 Futr Bio Ltda. Next generation mrna vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
TR201806655T4 (tr) * 2002-05-03 2018-06-21 The Government Of The Secretary Department Of Health And Human Services Dang tipi 4 genomunun 3' translate edilmemiş bölgesinin bir kesitinde bir 30 nükleotit delesyonunu (delta30) içeren bir rden3/4delta 30(me), rden2/4delta30(me) ya da rden1/4delta30(me) rekombinant kimerik dang virüsü olup, burada adı geçen 30 nükleotit delesyonu tl2 stem-loop yapısına karşılık gelir.
US7851194B2 (en) * 2004-06-14 2010-12-14 The United States Of America As Represented By The Department Of Health And Human Services West Nile viruses with mutations in the 3′ terminal stem and loop secondary structure for use as live virus vaccines
HUE029333T2 (en) * 2006-08-15 2017-03-28 The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Development of Dengue virus vaccine components

Also Published As

Publication number Publication date
BRPI0716455A8 (pt) 2019-01-15
PT2589602T (pt) 2016-07-13
WO2008022196A2 (en) 2008-02-21
BR122020023372B1 (pt) 2021-11-30
ES2585553T3 (es) 2016-10-06
CN101657463B (zh) 2013-09-18
US20100104598A1 (en) 2010-04-29
EP2589602B1 (en) 2016-04-06
CY1118003T1 (el) 2017-05-17
LT2589602T (lt) 2016-10-10
HUE029333T2 (en) 2017-03-28
EP2054428B9 (en) 2013-11-13
EP2054428A2 (en) 2009-05-06
US20130089567A1 (en) 2013-04-11
USRE46042E1 (en) 2016-06-28
US10724007B2 (en) 2020-07-28
BRPI0716455A2 (pt) 2014-03-04
CN101657463A (zh) 2010-02-24
US20200318083A1 (en) 2020-10-08
US10160957B2 (en) 2018-12-25
US11746335B2 (en) 2023-09-05
AU2007285929A2 (en) 2009-04-23
WO2008022196A3 (en) 2009-03-12
US20220251521A1 (en) 2022-08-11
CA3004991A1 (en) 2008-02-21
EP2054428B1 (en) 2013-06-05
CA3004991C (en) 2022-08-30
AU2007285929A1 (en) 2008-02-21
DK2589602T3 (da) 2016-07-25
CN103602689B (zh) 2016-08-24
CN103602689A (zh) 2014-02-26
US9090873B2 (en) 2015-07-28
EP2589602A3 (en) 2013-10-09
US20240084269A1 (en) 2024-03-14
EP2589602A2 (en) 2013-05-08
SI2589602T1 (sl) 2016-08-31
CA2661296A1 (en) 2008-02-21
CA2661296C (en) 2018-06-26
US20180171308A1 (en) 2018-06-21
PL2589602T3 (pl) 2016-11-30
US20190119654A1 (en) 2019-04-25
US11332722B2 (en) 2022-05-17
US8337860B2 (en) 2012-12-25
AU2007285929B2 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
DK2054428T3 (da) Udvikling af bestanddele til denque-virus-vaccine
CY2015004I1 (el) Αναστολεις του ιου της ηπατιτιδας c
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
BRPI0809600A2 (pt) vírus atenuado útil para vacinas
DK1896065T3 (da) Fremgangsmåde til fremstilling af vacciner
DK2066354T3 (da) Norovirus vaccine formuleringer
DK2046264T3 (da) Fremgangsmåder til fremstillingen af sammensætninger med film
ATE450271T1 (de) Impfstoff
DK1858917T3 (da) Varicella-zoster-virus-vaccine
DE602007002929D1 (de) Lichtempfindliche Zusammensetzung
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
DK2019680T3 (da) Forøgelse af titer til vaccination af dyr
DK2431359T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK1852430T3 (da) Fremgangsmåde til fremstilling af proanthocyanidinoligomer
CR10571A (es) Vacuna virica recombinante
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK2084174T3 (da) Fremstilling af ribofuranosylpyrimidinnukleotider
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK2049559T3 (da) Forbedrede HPV vacciner
DK2180938T3 (da) Fremgangsmåde til rengøring af røggas
DK2061803T3 (da) Fremgangsmåde til oprensning af fc-holdige proteiner
DK3300743T3 (da) Fremgangsmåder til indgivelse af vaccine
BRPI0821252A2 (pt) Anticorpos ao vírus da hepatite c
DK2043682T3 (da) Influenzavaccine